Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam besylate plus hydromorphone vs propofol plus sufentanil for induction in elderly
ChiCTR2300074907Phase 4Not yet recruiting
- Sponsor
- Ningjin County People's Hospital
- Start
- Aug 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam, hydromorphone, propofol and sufentanil in None (2 arms), sponsored by Ningjin County People's Hospital. Primary endpoints: Systolic blood pressure, Diastolic blood pressure and 2 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
remimazolamhydromorphonepropofolsufentanil
Beyond the preview
Go deeper on ChiCTR2300074907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074907.